PROK

ProKidney Corp. Class A Ordinary Shares

1.77

USD

PROK Earnings Reports

Positive Surprise Ratio

PROK beat 11 of 14 last estimates.

79%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

ProKidney Corp. Class A Ordinary Shares earnings per share and revenue

On Mar 18, 2026, PROK reported earnings of -0.14 USD per share (EPS) for Q4 25, missing the estimate of -0.12 USD, resulting in a -12.90% surprise. Revenue reached 225.00 thousand, compared to an expected 153.00 thousand, with a 47.06% difference. The market reacted with a -4.44% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Context Therapeutics Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.14

Surprise

-29.39%

Avalo Therapeutics, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$1.49

Actual

-$1.12

Surprise

+24.33%

Journey Medical Corporation Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.04

Surprise

+31.86%

Surrozen, Inc. Common

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$1.21

Actual

Surprise

Achieve Life Sciences, Inc.

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.12%

Vivani Medical, Inc. Common Stock (DE)

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.09

Surprise

Pyxis Oncology, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Acrivon Therapeutics, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.47

Actual

-$0.52

Surprise

-9.34%

Fractyl Health, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

$0.15

Surprise

+181.70%

NRX Pharmaceuticals, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.01

Surprise

-361.54%

FAQ

What were ProKidney Corp. Class A Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, ProKidney Corp. Class A Ordinary Shares reported EPS of -$0.14, missing estimates by -12.9%, and revenue of $225.00K, 47.06% above expectations.

How did the market react to ProKidney Corp. Class A Ordinary Shares's Q4 2025 earnings?

The stock price moved down -4.44%, changed from $2.25 before the earnings release to $2.15 the day after.

When is ProKidney Corp. Class A Ordinary Shares expected to report next?

The next earning report is scheduled for --.

What are the forecasts for ProKidney Corp. Class A Ordinary Shares's next earnings report?

Based on -- analysts, ProKidney Corp. Class A Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.